ClinicalTrials.gg

Amyloidosis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 290 studies for Amyloidosis across more than 10 countries. 92 are recruiting or about to start. 145 of them are mainly about Amyloidosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 7 narrower conditions too, such as Immunoglobulin Light-chain Amyloidosis: 689 studies, 228 open.

Status

Completed
131
Recruiting
70
Not yet recruiting
18
Terminated
17
Status unknown
17
Withdrawn
15

Phase

Phase 2
82
Phase 1
54
Phase 3
43
Phase 4
5
Early Phase 1
5

Where

United States
141
France
56
Italy
52
United Kingdom
49
Spain
48
Germany
44

Who develops what

Add Amyloidosis to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 13 programs from 12 companies, 10 with this as their studies’ main aim; 6 with a live phase 3 study; 1 primary completion in the next 12 months. Compare AstraZeneca, AbbVie and Alnylam Pharmaceuticals here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
CyclophosphamideRecent, repeated
Evidence
  • NCT07901725 · Regeneron Pharmaceuticals · Phase 3 · live · comparator · “Cyclophosphamide” · registered Oct 2026
  • NCT07793422 · AbbVie · Phase 3 · live · comparator · “Cyclophosphamide” · registered Aug 2026
  • NCT07388602 · Sinocelltech Group Limited · Phase 3 · live · background · “Cyclophosphamide” · registered Jan 2026
  • NCT05250973 · Johnson & Johnson · Phase 2 · live · background · “Cyclophosphamide” · registered Feb 2022
  • NCT03201965 · Johnson & Johnson · Phase 3 · comparator · “Cyclophosphamide” · registered Jun 2017
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed44 studies
DexamethasoneRecent, repeated
Evidence
  • NCT07901725 · Regeneron Pharmaceuticals · Phase 3 · live · comparator · “Dexamethasone” · registered Oct 2026
  • NCT07793422 · AbbVie · Phase 3 · live · comparator · “Dexamethasone” · registered Aug 2026
  • NCT07388602 · Sinocelltech Group Limited · Phase 3 · live · background · “Dexamethasone” · registered Jan 2026
  • NCT05250973 · Johnson & Johnson · Phase 2 · live · background · “Dexamethasone” · registered Feb 2022
  • NCT03201965 · Johnson & Johnson · Phase 3 · comparator · “Dexamethasone, 40 mg” · registered Jun 2017
AbbVie11% of its industry studiesUS: off-patent, 28 generics marketedEU: Norgine (EMA 2016)44 studies
BortezomibRecent, repeated
Evidence
  • NCT07901725 · Regeneron Pharmaceuticals · Phase 3 · live · comparator · “Bortezomib” · registered Oct 2026
  • NCT07793422 · AbbVie · Phase 3 · live · comparator · “Bortezomib” · registered Aug 2026
  • NCT07388602 · Sinocelltech Group Limited · Phase 3 · live · background · “Bortezomib” · registered Jan 2026
Johnson & Johnson33% of its industry studiesUS: off-patent, 15 generics marketedEU: off-patent, 3 generics authorized33 studies
daratumumabRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07901725 · Regeneron Pharmaceuticals · Phase 3 · live · comparator · “Daratumumab” · registered Oct 2026
  • NCT07793422 · AbbVie · Phase 3 · live · comparator · “Daratumumab” · registered Aug 2026
Johnson & Johnson64% of its industry studies22 studies

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Anti-CD38 Monoclonal Antibody SCTC21C☆ Track1 live phase-3 study: NCT07388602Sinocelltech Group Limited
nucresiran☆ Track2 live phase-3 studies: NCT07052903, NCT07223203Alnylam Pharmaceuticals
Evarucabgene Autoleucel☆ Track1 live phase-3 study: NCT07709715Nexcella Inc.
acoramidisApproved: EU 2025☆ Track2 live phase-3 studies: NCT07116473, NCT06563895BridgeBio
etentamig☆ Track1 live phase-3 study: NCT07793422AbbVie

The 5 in phase 3 with the nearest primary completion, of 13 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.Evarucabgene Autoleucel · Nexcella Inc. · Phase 2 named, not the main aimNCT06097832 Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis — primary endpoint: Number of Participants With Treatment-Related Adverse Events · 45 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Amyloidosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Alkylating agents 1 open · Proteasome inhibitors 1 open

Coming up

28studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger. 7 (10%) take children under 18. 1 (1%) are for women only and 0 (0%) for men only; 9 (13%) take healthy volunteers.

Recruiting studies that take each age, of 70
AgeWomenMen
107 (10%)6 (9%)
1861 (87%)60 (86%)
3064 (91%)63 (90%)
4066 (94%)65 (93%)
5067 (96%)66 (94%)
6570 (100%)69 (99%)
7569 (99%)68 (97%)
8556 (80%)55 (79%)

Across all 290 studies, recruiting or not: 14% stop at 75 or younger and 7% at 65; 7% take children; <1% are for women only and <1% for men only; 12% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Amyloidosis studies take

Of 25 phase 3 interventional studies under Amyloidosis, half reached primary completion within 53 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 131 mo6–58 · 18 studies——
Phase 247 mo33–64 · 24 studies——
Phase 353 mo40–74 · 25 studies——
Interventional, no phase35 mo25–75 · 26 studies——
Observational97 mo29–183 · 52 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 290. Browse all 290 → or search them.